C A S E R E P O R T
A Case of Recurrent Multifocal Central Giant Cell Granulomas
Elizabeth BilodeauÆ Khalid Chowdhury Æ Bobby Collins
Received: 10 November 2008 / Accepted: 8 May 2009 / Published online: 11 June 2009 Ó Humana 2009
Abstract One case of recurrent multifocal central giant cell granulomas (CGCG) is presented. Initially, the lesions presented concurrently in the maxilla and mandible with subsequent recurrence in the mandible. Now, two recur- rences are seen in the maxillary sinus and ethmoid region.
The literature regarding multifocal CGCG is reviewed.
Keywords Central giant cell granulomas (CGCG) Reparative giant cell granuloma
Craniofacial giant cell dysplasia
Introduction
The central giant cell granuloma (CGCG) affects females more often than males, in a 2:1 ratio and is seen most fre- quently under the age of 30 years [1]. One study of 38 patients shows 74% to be less than 30 years of age and 61%
to be less than 20 years of age [2]. The lesion commonly presents as a solitary radiolucency with a multilocular appearance or less commonly, a unilocular appearance [2–4]. It is more prevalent in the anterior than the posterior jaws, often crossing the midline, and the mandible is more commonly affected than the maxilla [2,4]. This lesion has
also been reported in the small bones of the hands and feet [5,6]. The behavior of CGCG is variable, most commonly producing asymptomatic expansion of the jaws [7]. How- ever, it can be clinically aggressive, associated with pain, osseous destruction, cortical perforation, root resorption, and recurrence [8]. Cases of CGCG occurring with neuro- fibromatosis (type 1) [7, 9–11], Noonan-like syndrome [12,13], or both [7,14] have been reported.
The treatment of CGCG includes simple curettage or curettage with peripheral ostectomy; Resection for lesions of the maxilla or paranasal sinuses has been advocated as the thin bony cortices and sinuses do not provide a good anatomic barrier [15]. Corticosteroids and calcitonin are used for non-surgical management [16, 17]. Interferon alpha therapy has also been used as a postoperative adju- vant and to prevent tumor progression [18,19].
Report of a Case
This patient’s histological slides were referred to the Uni- versity of Pittsburgh Medical Center for pathology consul- tation. Her medical records were subsequently obtained. The patient was a 42-year-old female with a history of multifocal giant cell lesions in the left mandible and left maxilla. A year after her initial diagnosis and treatment, a recurrent lesion was noted in the left mandible and subsequently curetted.
Two and a half years after the initial lesions, this was the second recurrent episode. This recurrence, the patient pre- sented with two distinct lesions the larger, inferior lesion filling much of the maxillary sinus and the smaller, superior lesion adjacent to the ethmoid region. A comprehensive laboratory assessment to rule out hyperparathyroidism revealed: calcium (serum) 9.8 (normal 8.5–10.4 mg/dl), PTH (intact) 58 pg/ml (normal 12–65 pg/ml), phosphorus E. Bilodeau (&) B. Collins
Department of Diagnostic Sciences, University of Pittsburgh School of Dental Medicine, Pittsburgh, PA, USA
e-mail: rodeea@upmc.edu B. Collins
e-mail: bcollins@dental.pitt.edu K. Chowdhury
Center for Craniofacial & Skull Base Disorders/Department of Otolaryngology, University of Colorado, Denver, CO, USA e-mail: craniofacial@qwestoffice.net
DOI 10.1007/s12105-009-0119-0
(serum) 2.9 mg/dl (normal 2.5–4.5 mg/dl), albumin 5.1 (normal 3.7–5.1 g/dl), urine calcium level of 6.4 mg/dl (normal, not established), and urine 24 h calcium 185.4 mg/
24 h (normal 100.0–300.00 mg/24 h). Other laboratory values were within normal limits, except for a bilirubin of 1.8 mg/dl (normal 0.1–1.2 mg/dl). The patient had known Gilbert’s syndrome.
The patient’s clinical appearance was phenotypically normal, not that of Noonan’s syndrome. Although we are uncertain what testing was performed, a comprehensive workup revealed the patient was negative for Noonan’s syndrome and hyperparathyroidism.
On magnetic resonance imaging (MRI), two lesions were seen (see Fig.1). The lesions were heterogeneously hyper- intense on T2 weighted imaging and isointense to brain on T1 weighted imaging with enhancement. The larger of the two recurrent lesions was 3.1 9 2.9 9 2.6 cm encompass- ing the roots of the maxillary posterior teeth and deviating the inferior turbinate (see Fig.2). The second lesion was 2.4 9 2.3 9 2.1 cm and was located inferior to the medial floor of the left orbit. Invasion of the medial wall of the left maxillary sinus with bulging into the nasal cavity and thin- ning of the posterolateral maxillary sinus wall with tumor bulging into the retromaxillary fat pad was seen.
A left endoscopic ethmoidectomy was performed using an image guidance mask. The recurrent left maxillary giant cell granuloma (GCG) was excised via intraoral approach.
The maxillary lesion was removed, followed by stripping of the maxillary sinus mucosa to bone. The maxillary sinus
was reconstructed with demineralized bone matrix and autogenous platelet rich plasma.
The two pathology specimens from the left ethmoid region and maxillary sinus were histologically similar, revealing abundant diffusely distributed multinucleated central giant cells (see Fig. 3). The hypercellular fibrous stroma was composed of mononuclear spindle shaped cells and scattered ovoid cells. Cystic areas of extravasated nonendothelialized hemorrhage, resembling an aneurysmal
Fig. 1 T1 weighted MRI of the tumors on sagittal section demon- strating proximity to the dentition and the ethmoid region
Fig. 2 T2 weighted MRI of the larger inferior lesion on coronal section demonstrating deviation of inferior turbinate
Fig. 3 Photomicrograph from first recurrence of the left maxillary CGCG showing multinucleated giant cells in a spindle or ovoid shaped fibrovascular connective tissue stroma (H&E, 910)
bone cyst, and minimal mitotic activity were observed but no cellular atypia was observed.
Discussion
Much controversy surrounds the CGCG. Initially, it was not distinguished from the giant cell tumor of the extra- gnathic skeleton [20], but later it was described by Jaffe as the giant cell reparative granuloma [21]. Some authorities advocate using the more neutral term ‘‘central giant cell lesion’’ to describe this process, but most accept CGCG.
CGCG has been proposed to be both a reactive response, to hemorrhage or trauma, and a neoplasm [2, 3, 22]. Some have proposed that giant cell granuloma of the jaws and giant cell tumors (GCT) of the extragnathic skeleton are part of a spectrum of a single lesion, modified by anatomic site [2, 15]. However, others have viewed CGCGs and GCTs of the extragnathic skeleton as distinct lesions [21, 23, 24]. Certain histological differences exist between the CGCG and the GCT (see Table1). The giant cells are more evenly distributed in the GCT, focal areas of necrosis exist, decreased fibrous tissue is present, and an accumulation of inflammatory cells may be seen [25]. Histologically, CGCG resembles the giant cell lesion of hyperparathy- roidism, cherubism, and aneurysmal bone cyst, which must be excluded. Multiple central giant cell lesions have been reported in association with Noonan-like/multiple giant cell lesion syndrome, and other features of the disease include a short stature, webbed neck, cubitus valgus, pul- monic stenosis, and multiple lentigenes [26].
Immunohistochemical studies on CGCG have helped establish the lineage of the cells, but not to predict the aggressiveness of the lesion. Supporting the theory that the
multinucleated giant cells are derived from macrophages is the immunoreactive response to muramidase, a-1 antichy- motrypsin, and a-1 antitrypsin [27]. Aggressive and non- aggressive CGCGs stained for antibodies to CD34, CD68, factor Xllla, and smooth muscle actin, prolyl 4-hydroxy- lase, Ki-67, p53 protein, RANK, and glucocorticoid receptor alpha have revealed no phenotypic differences between the types [28,29]. Calcitonin receptor expression, however, has been found to exhibit a statistically signifi- cant difference with more expression in the aggressive type [29]. Immunohistochemical staining for c-Src, a protein thought to be required for osteoclast activation, has yielded no quantitative difference between CGCG, GCT, or cher- ubism [30]. The SH3BP2 gene is commonly found to be mutated in cherubism, and its transcripts and proteins have been found to be expressed in GCT and CGCG. [31] The mononuclear stromal cells display strong p63 immuno- staining in GCTs, but this has not been detected in CGCGs [32,33]. Thus, P63 is one immunohistochemical stain that may help distinguish GCT from CGCG, while also sug- gesting a differing pathogenesis.
Multifocal CGCG is a challenging entity. In previous reviews of the literature, different cases have been included as multifocal CGCG [34,35]. Previous cases of multiple giant cell lesions may represent:
1. Unusual reports of cherubism [36,37]
2. Association with a syndrome or genetic condition [14,15,38]
3. A single lesion of a jaw separated by normal bone 4. Association with elevated PTHrP [39]
5. True giant cell tumors originating in the maxillofacial region,
6. Multifocality resulting from hematogenous spread due to inadequate treatment
In total, we believe there are six convincing cases of multifocal CGCG of the maxillofacial skeleton previously reported and not better explained by other pathologic conditions (see Table2).
Smith et al. [40] have proposed a new term, ‘‘craniofa- cial giant cell dysplasia,’’ to describe the multifocal central giant cell of the jaws. Miloro and Quinn [34] advocate dividing multifocal central giant cell lesions into syn- chronous or metachronous lesions. They propose metach- ronous lesions are more likely to represent a recurrence due to inadequate initial treatment or tumor seeding, whereas synchronous lesions are more likely to represent true multifocality.
Our case represents a clinically aggressive, multifocal, and recurrent CGCG that is quite bland histologically, and not associated with other conditions or syndromes. It dis- plays a secondary aneurysmal bone cyst component seen in 30% of CGCG [41] as well as other osseous lesions [42].
Table 1 Comparison of giant cell tumor and central giant cell granuloma
Giant cell tumor Central giant cell granuloma Location Sphenoid, temporal, ethmoid
bones (endochondral ossification, not membranous in origin) Jaws in paget disease
Jaws, anterior mandible
Giant cells Evenly distributed Fewer, smaller giant cells, unevenly distributed Stromal cells Monocytes, osteoclasts
No intercellular collagen
Fibroblasts producing collagen;
Numerous capillaries
Osteoid No Yes
Given the small number of cases available, it is difficult to draw any conclusions. However, some trends may be observed. Similar to CGCG, there was a female predomi- nance, representing six of the seven patients. Slightly older populations than in most CGCGs were seen. The mean age in our review of published multifocal cases was 33 years, with only two of the seven patients younger than 30 years of age. It is possible that occult or inadequately treated CGCGs spread hematogenously, but this is not a traditional characteristic behavior of these lesions. Multifocal CGCGs are more aggressive than solitary CGCGs as exhibited by increased recurrence and osseous destruction. They should be treated with more aggressive surgical therapy as in five of seven cases the patients had a recurrence.
Central giant cell granuloma remains a challenge for pathologists. There are multiple conditions that must be ruled out clinically, and the controversy surrounding the etiology of this condition has yet to be definitively resolved.
Acknowledgments The authors would like to thank Drs. Leon Barnes, Simion Chiosea, and Raja Seethala for their comments on this paper.
References
1. Motamedi MH, Eshghyar N, Jafari SM, et al. Peripheral and central giant cell granulomas of the jaws: a demographic study.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod.
2007;103:39–43. doi:10.1016/j.tripleo.2006.12.022.
2. Waldron CA, Shafer WG. The central giant cell reparative granuloma of the jaws: an analysis of 38 cases. Am J Clin Pathol.
1966;45:437–47.
3. Whitaker SB, Waldron CA. Central giant cell lesions of the jaws:
a clinical, radiologic, and histopathologic study. Oral Surg Oral Med Oral Pathol. 1993;75:199–208. doi:10.1016/0030-4220(93) 90094-K.
4. Kaffe I, Ardekian L, Taicher S, et al. Radiologic features of central giant cell granuloma of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996;81:720–6. doi:10.1016/S1079- 2104(96)80079-5.
5. Lorenzo JC, Dorfman HD. Giant-cell reparative granuloma of short tubular bones of the hands and feet. Am J Surg Pathol.
1980;4:551–63. doi:10.1097/00000478-198012000-00006.
6. Glass TA, Mills SE, Fechner RE, et al. Giant-cell reparative granuloma of the hands and feet. Radiology. 1983;149:65–8.
7. De Lange J, Van den Akker HP. Clinical and radiological fea- tures of central giant-cell lesions of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005;99:464–70. doi:10.1016/
j.tripleo.2004.11.015.
8. Kruse-Losler B, Diallo R, Gaertner C, et al. Central giant cell granuloma of the jaws: a clinical, radiologic, and histopathologic study of 26 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;101:346–54. doi:10.1016/j.tripleo.2005.02.060.
9. Ardekian L, Manor R, Peled M, et al. Bilateral central giant cell granulomas in a patient with neurofibromatosis: report of a case and review of the literature. J Oral Maxillofac Surg. 1999;57:
869–72. doi:10.1016/S0278-2391(99)90833-9.
10. Ruggieri M, Pavone V, Polizzi A, et al. Unusual form of recurrent giant cell granuloma of the mandible and lower extremities in a patient with neurofibromatosis type 1. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999;87:67–72. doi:10.1016/S1079- 2104(99)70297-0.
11. Edwards PC, Fantasia JE, Saini T, et al. Clinically aggressive central giant cell granulomas in two patients with neurofibro- matosis 1. Oral Surg Oral Med Oral Pathol Oral Radiol Endod.
2006;102:765–72. doi:10.1016/j.tripleo.2005.10.038.
12. Cohen MM Jr, Gorlin RJ. Noonan-like/multiple giant cell lesion syndrome. Am J Med Genet. 1991;40:159–66. doi:10.1002/ajmg.
1320400208.
13. Cancino CM, Gaiao L, Sant’Ana Filho M, et al. Giant cell lesions with a Noonan-like phenotype: a case report. J Contemp Dent Pract. 2007;8:67–73.
Table 2 Characteristics of multifocal central giant cell granulomas
Reference Age/Sex Location at initial presentation
Recurrence
Davis and Tideman [43] 31/F R mandibular body 4 months L maxilla 1 year L maxilla 2 years R mandible
Smith et al. [40] 41/F R mandibular angle 9 years L maxillary sinus, nasal bone, orbital floor and R maxillary sinus Martins et al. [35] 35/F L maxilla
R mandible
5 years follow-up no recurrence
Loukota [44] 25/F R mandible 10 months L maxilla
No additional recurrence at 2 years Wise and Bridebord [45] 23/M L mandibular body
L and R nasomaxillary area
4 years follow-up no recurrence
Miloro and Quinn [34] 37/F L maxilla Ant. mandible
1 year L maxilla and ant mandible
Bilodeau, Chowdhury, and Collins
42/F L mandible L maxilla
1 year L mandible
2 years L maxillary sinus/ethmoid region
14. van Damme PA, Mooren RE. Differentiation of multiple giant- cell lesions, Noonan-like syndrome, and (occult) hyperparathy- roidism: case report and review of the literature. Int J Oral Maxillofac Surg. 1994;23:32–6. doi:10.1016/S0901-5027(05) 80323-6.
15. Stolovitzky JP, Waldron CA, McConnel FMS. Giant cell lesions of the maxilla and paranasal sinuses. Head Neck. 1994;16:143–8.
doi:10.1002/hed.2880160207.
16. Terry BC, Jacoway JR. Management of central giant cell lesions:
an alternative to surgical therapy. Oral Maxillofac Surg Clin North Am. 1994;6:579–600.
17. de Lange J, van den Akker HP, Veldhuijzen van Zanten GO, et al.
Calcitonin therapy in central giant cell granuloma of the jaw: a randomized double-blind placebo-controlled study. Int J Oral Maxillofac Surg. 2006;35:791–5. doi:10.1016/j.ijom.2006.03.030.
18. de Lange J, van den Akker HP, van den Berg H, et al. Limited regression of central giant cell granuloma by interferon alpha after failed calcitonin therapy: a report of 2 cases. Int J Oral Maxillofac Surg. 2006;35:865–9. doi:10.1016/j.ijom.2006.02.011.
19. Kaban LB, Troulis MJ, Ebb D, et al. Antiangiogenic therapy with interferon alpha for giant cell lesions of the jaws. J Oral Max- illofac Surg. 2002;60:1103–11. doi:10.1053/joms.2002.34975.
20. Bernick S. Central giant cell tumors of the jaws. J Oral Surg.
1948;6:324.
21. Jaffe H. Giant cell reparative granuloma, traumatic bone cyst, and fibrous (fibro-osseous) dysplasia of the jaw bones. Oral Surg Oral Med Oral Pathol. 1953;6:159–75. doi:10.1016/0030-4220(53) 90151-0.
22. Shklar G, Meyer I. A giant-cell tumor of the maxilla in an area of osteitis deformans (Paget’s disease of bone). Oral Surg Oral Med Oral Pathol. 1958;11:835–42. doi:10.1016/0030-4220(58) 90198-1.
23. Austin L, Dahlin D, Royer R. Giant-cell reparative granuloma and related conditions affecting the jawbones. Oral Surg Oral Med Oral Pathol. 1959;12:1285–95. doi:10.1016/0030-4220(59) 90215-4.
24. Abrams B, Shear M. A histological comparison of the giant cells in central giant cell granuloma of the jaws and the giant cell tumor of long bone. J Oral Pathol. 1974;3:217–23. doi:10.1111/
j.1600-0714.1974.tb01714.x.
25. Auclair PL, Kratochvil FJ, Slater LJ, et al. A clinical and histo- morphologic comparison of the central giant cell granuloma and giant cell tumor. Oral Surg Oral Med Oral Pathol. 1988;66:197–
208. doi:10.1016/0030-4220(88)90094-1.
26. Cohen MM Jr, Gorlin RJ. Noonan-like/multiple giant cell lesion syndrome. Am J Med Genet. 1991;40:159–66. doi:10.1002/
ajmg.1320400208.
27. Regezi JA, Zarbo RJ, Lloyd RV. Muramidase, alpha-1 antitryp- sin, alpha-1 antichymotrypsin, and S-100 protein immunoreac- tivity in giant cell lesions. Cancer. 1987;59:64–8. doi:10.1002/
1097-0142(19870101)59:1\64::AID-CNCR2820590116[3.0.
CO;2-Q.
28. O’Malley M, Pogrel MA, Stewart JC, et al. Central giant cell granulomas of the jaws: phenotype and proliferation-associated markers. J Oral Pathol Med. 1997;26:159–63. doi:10.1111/j.1600- 0714.1997.tb00451.x.
29. Tobon-Arroyave SI, Franco-Gonzalez LM, Isaza-Guzman DM, et al. Immunohistochemical expression of RANK, GRalpha and CTR in central giant cell granuloma of the jaws. Oral Oncol.
2005;41:480–8. doi:10.1016/j.oraloncology.2004.11.006.
30. Wang C, Song Y, Peng B, et al. Expression of c-Src and com- parison of cytologic features in cherubism, central giant cell granuloma and giant cell tumors. Oncol Rep. 2006;15:589–94.
31. Lietman SA, Prescott NL, Hicks DG, et al. SH3BP2 is rarely mutated in exon 9 in giant cell lesions outside cherubism. Clin Orthop Relat Res. 2007;459:22–7. doi:10.1097/BLO.0b013e3 1804b4131.
32. Lee CH, Espinosa I, Jensen KC, et al. Gene expression profiling identifies p63 as a diagnostic marker for giant cell tumor of the bone. Mod Pathol. 2008;21:531–9. doi:10.1038/modpathol.
3801023.
33. Dickson BC, Li SQ, Wunder JS, et al. Giant cell tumor of bone express p63. Mod Pathol. 2008;21:369–75. doi:10.1038/
modpathol.2008.29.
34. Miloro M, Quinn PD. Synchronous central giant cell lesions of the jaws: report of a case and review of the literature. J Oral Maxillofac Surg. 1995;53:1350–5. doi:10.1016/0278-2391(95)90600-2.
35. Martins WD, de Oliveira Ribas M, Braosi AP, et al. Multiple giant cell lesions of the maxillofacial skeleton. J Oral Maxillofac Surg. 2007;65:1250–3. doi:10.1016/j.joms.2005.10.046.
36. Cassatly MG, Greenberg AM, Kopp WK. Bilateral giant cell granulomata of the mandible: report of a case. J Am Dent Assoc.
1988;117:731–3.
37. Weldon L, Cozzi G. Multiple giant cell lesions of the jaws.
J Oral Maxillofac Surg. 1982;40:520–2. doi:10.1016/0278-2391 (82)90016-7.
38. Curtis NJ, Walker DM. A case of aggressive multiple metach- ronous central giant cell granulomas of the jaws: differential diagnosis and management options. Int J Oral Maxillofac Surg.
2005;34:806–8. doi:10.1016/j.ijom.2005.01.010.
39. Davis JP, Archer DJ, Fisher C, et al. Multiple recurrent giant cell lesions associated with high circulating levels of parathyroid hormone-related peptide in a young adult. Br J Oral Maxillofac Surg. 1991;29:102–5. doi:10.1016/0266-4356(91)90092-J.
40. Smith PG, Marrogi AJ, Delfino JJ. Multifocal central giant cell lesions of the maxillofacial skeleton: a case report. J Oral Max- illofac Surg. 1990;48:300–5. doi:10.1016/0278-2391(90)90398-L.
41. Struthers PJ, Shear M. Aneurysmal bone cyst of the jaws. (II).
Pathogenesis. Int J Oral Surg. 1984;13:92–100. doi:10.1016/
S0300-9785(84)80078-2.
42. Levy W, Miller A, Bonakdarpour A, et al. Aneurysmal bone cyst secondary to other osseous lesions: report of 57 cases. Am J Clin Pathol. 1975;63:1–8.
43. Davis GB, Tideman H. Multiple recurrent central giant cell granulomas of the jaws. J Maxillofac Surg. 1977;5:127–9.
doi:10.1016/S0301-0503(77)80089-1.
44. Loukota RA. Metachronous and recurrent central giant cell granulomas: a case report. Br J Oral Maxillofac Surg. 1991;29:
48–50. doi:10.1016/0266-4356(91)90175-5.
45. Wise AJ, Bridbord JW. Giant cell granuloma of the facial bones.
Ann Plast Surg. 1993;30:564–8. doi:10.1097/00000637-19930 6000-00019.
